CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
SOM230 LARdrug
Likely dose
SOM230 LAR 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02021942
NCT02021942Phase 2Completed
CompareCT.gov

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Prof. Dr. Berthold Schalke·interventional·Posted Dec 27, 2013·Updated Feb 5, 2018

In Brief

A Phase 2 clinical trial evaluating SOM230 LAR for Primary Inoperable Thymoma and Local Recurrent Thymoma. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This is a monocenter, single-arm, open label phase II trial evaluating the effect of SOM230 LAR in adult patients with inoperable primary thymoma and thymoma metastasis (Masaoka II-IVa). SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks. The purpose of this trial is a proof of concept.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Inoperable Thymoma, Local Recurrent Thymoma
CountriesGermany
CollaboratorsCrolll Gmbh

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 27, 2013
Enrollment StartMar 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.5 years ago

Interventions

SOM230 LARdrug

SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.